Six melanoma specialists said the Moderna and Merck vaccine results represent a clinically meaningful advance in melanoma ...

Merck CEO Rob Davis joins 'Squawk on the Street' to discuss leaked data of melanoma vaccine trials, the drop off the ...

A first-of-its-kind vaccine against cancer may be on the horizon.

Merck (MRK) stock returned 78.7% in the twelve months to October 21, 2026, against 16.5% for the S&P 500. Over that year, ...

Merck KGaA agreed to acquire Silence Therapeutics Plc for about $1.1 billion in a cash transaction as the German science ...

Shares of Merck (MRK) returned 76.2% over the past year, compared with 17.4% for the S&P 500. U.S. growth for the company's ...

Moderna's personalized melanoma vaccine just posted positive late-stage results alongside Merck, yet shares keep sliding ...

Merck stock looks fairly valued as Keytruda risks, slower EPS growth, and debt weigh on upside. Click here to read an ...

For now, the vaccine is not far from potentially entering the market for the first time and reaching melanoma patients. In an ...

Halozyme makes technologies that allow drugs delivered through intravenous infusion, or IV, to instead be given with ...

US pharma major Merck & Co (NYSE: MRK) and US biotech Moderna (Nasdaq: MRNA) have reported detailed Phase III results showing ...

Pfizer's 5.7% dividend yield towers over Merck's, yet that gap may signal something retirees cannot afford to ignore. Before ...